All Publications

• Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The NetherlandsAbstract

  PURPOSE: In June 2013 a European Medicines Agency referral procedure concluded that diclofenac was associated with an elevated risk of acute cardiovascular events and contraindications, warnings, and changes to the product information were implemened across the European Union. This study measured the impact of the regulatory action on the prescribing of systemic diclofenac in Denmark, The Netherlands, England, and Scotland

  Morales DR, Morant SV, MacDonald TM, Mackenzie IS, Doney ASF, Mitchell L, Bennie M, Robertson C, Hallas J, Pottegard A, Ernst MT, Wei L, Nicholson L, Morris C, M CR, Overbeek JA, Smits E, W VR. Pharmacoepidemiol Drug Saf. 2020 Jan 4;

• No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization StudyAbstract

  To characterize the use of olodaterol and indacaterol in clinical practice and to quantify the off-label use in asthma. Drug utilization study of new users of olodaterol or indacaterol between 2014 and 2017 in the PHARMO Database Network in the Neterlands, the Danish population registers, and the IMS Real-World Evidence Longitudinal Patient Database panels in France

  Rebordosa C, Houben E, Laugesen K, Bothner U, Montonen J, Aguado J, Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW. Sci Rep. 2020 Jan 17; 10 586.

• Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetesAbstract

  BACKGROUND: Quality of diabetes care in the Netherlands ranked second in the Euro Diabetes Index 2014, but data on outcomes are lacking. We assessed trends in cardiovascular disease and mortality among type 2 diabetes (T2DM) patients in the contextof risk factor control. METHODS: Annual cohorts of adult T2DM patients were constructed from the PHARMO Database Network

  Heintjes EM, Houben E, Beekman-Hendriks WL, Lighaam E, Cremers SM, Penning-van Beest FJA, Stehouwer CDA, Herings RMC. Neth J Med. 2019 Dec; 77 317-329.

• The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depressionAbstract

  OBJECTIVE: To examine the associations between pharmaceutically treated anxiety and depression and incident cardiovascular disease (CVD) among 1-year prostate cancer survivors. PATIENTS AND METHODS: A registry-based cohort study design was used toescribe the risk of incident CVD in adult 1-year prostate cancer survivors without a history of CVD

  Wollersheim BM, Boekhout AH, van der Poel HG, van dePoll-Franse LV, Schoormans D. BJU Int. 2019 Nov 26;

• Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetesAbstract

  PURPOSE: The prevalence of colorectal cancer is higher among patients with type 2 diabetes mellitus (T2D) than among patients without diabetes. Furthermore, men are at higher risk for developing colorectal cancer than women in the general populatioand also subsite-specific risks differ per sex. The aim was to evaluate the impact of T2D on these associations

  Overbeek JA, Kuiper JG, van der Heijden Aawa, Labots M, Haug U, Herings RMC, Nijpels G. Int J Colorectal Dis. 2019 Nov 12; 34 269-276.

• Compliance with the guidelines for laboratory monitoring of patients treated with lithium: a retrospective follow-up study among ambulatory patients in the NetherlandsAbstract

  OBJECTIVES: Laboratory monitoring of patients using lithium is important to prevent harm and to increase effectiveness. The aim of this study is to determine compliance with the guidelines for laboratory monitoring of patients treated with lithiumverall and within subgroups. METHODS: Patients having at least one lithium dispensing for six months or longer between January 2010 and December 2015 were identified retrospectively using data from the Dutch PHARMO Database Network

  Neder lof M, Egberts TCG, van Londen L, deRotte Mcfj, Souverein PC, Herings RCM, Heerdink ER. Bipolar Disord. 2019 Nov 25; 21 419-427.

• Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countriesAbstract

  AIMS: Various drugs increase the risk of out-of-hospital cardiac arrest (OHCA) in the general population by impacting cardiac ion channels, thereby causing ventricular tachycardia/fibrillation (VT/VF). Dihydropyridines block L-type calcium channelsbut their association with OHCA risk is unknown. We aimed to study whether nifedipine and/or amlodipine, often-used dihydropyridines, are associated with increased OHCA risk, and how these drugs impact on cardiac electrophysiology

  Eroglu TE, Mohr GH, Blom MT, Verkerk AO, Souverein PC, Torp-Peder sen C, Folke F, Wissenberg M, van den Brink L, Davis RP, deBoer A, Gislason GH, Tan HL. Eur Heart J Cardiovasc Pharmacother. 2019 Sep 11;

• Effect of reimbursement restriction policy on the use of benzodiazepines in the Netherlands: an interrupted time series analysisAbstract

  OBJECTIVES: Use of benzodiazepines has health risks. Reimbursement was restricted in the Netherlands from January 2009 onwards with the goal to reduce chronic use and healthcare expenditures. The aim of this study is to assess the initial and long-erm effects of this policy on benzodiazepine use. DESIGN: Interrupted time series analysis, segmented regression models, Kaplan-Meier survival analysis and Cox proportional hazards analysis

  Stoker LJ, Heerdink ER, Janssen R, Egberts TCG. BMJ Open. 2019 Sep 24; 9 e029148.

• Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control studyAbstract

  Aims: Non-steroidal anti-inflammatory drugs (NSAIDs), particularly selective COX-2 inhibitors, are associated with an increased risk of cardiovascular adverse events. However, the association between these drugs and out-of-hospital cardiac arrest wth electrocardiogram-documented ventricular tachycardia/ventricular fibrillation (VT/VF-OHCA) has not been studied yet

  Bakhriansyah M, Souverein PC, Klungel OH, de Boer A, Blom MT, Tan HL. Europace. 2019 Aug 10; 21 99-105.

• Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitionsAbstract

  PURPOSE: The antiarrhythmic drug amiodarone has a long half-life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use andthe risk of acute pancreatitis. METHOD: Using data from the Dutch PHARMO Database Network, incident amiodarone users were compared to incident users of a different type of antiarrhythmic drug

  Hempenius M, Groenwold RHH, de Boer A, Klungel OH, Gardarsdottir H. Pharmacoepidemiol Drug Saf. 2019 Aug 2; 28 1563-1571.